High Potency Active Pharmaceutical Ingredients Market revenue to cross USD 40,983.8 Million By 2027, at a CAGR of 9.9% between 2020 and 2027
High Potency Active Pharmaceutical Ingredients (HPAPI) can be roughly classified into brand name or generic drugs according to their customer base. Since HPAPI can target diseased cells more precisely and selectively than other APIs, the demand for HPAPI is increasing rapidly.
It is estimated that by the end of 2027, the global high potency active pharmaceutical ingredients market will reach US$ 4,983.82 million.
Request for Analysis of COVID-19 Impact on High Potency Active Pharmaceutical Ingredients Market –
During the forecast period, the increase in the release of antibody-drug conjugates is expected to drive the growth of the global high potency active pharmaceutical ingredients market. In January 2020, the antibody manufacturer Proteintech Group released more than 500 antibodies directly coupled with high-performance CoraLite488 and CoraLite594 dyes.
The significant growth of the pharmaceutical industry is expected to provide profitable growth opportunities for participants in the global high potency active pharmaceutical ingredients market. According to key data from the European Federation of Pharmaceutical Industries and Associations in 2019, the European pharmaceutical industry invested US $19,509 million in 2000 and increased to US$ 39.895 million in 2018.
Strict manufacturing regulations are expected to hinder the growth of the global high potency active pharmaceutical ingredients market.
The global high potency active pharmaceutical ingredients market in 2019 was US$ 19.258 million, and it is expected to reach US$ 40,983.82 million at a CAGR of 9.9 percent from 2020 to 2027. The global high potency active pharmaceutical ingredients market during the forecast period is projected to grow due to technological progress and increased product releases.
In 2019, the innovative molecular sector occupied a leading position in the global high-efficiency active pharmaceutical ingredient market, with a value share of 70.3%, followed by generic drugs. It is expected that during the forecast period, a strong portfolio of innovative molecules will support the growth of this market segment.
Request PDF Brochure Report –
Major market players focus on expanding production capacity to increase market share. In August 2020, SEQENS opened an innovative HPAPI unit at its Villeneuve LaGarenne plant in France for the production of highly active ingredients.
Key companies in the global high potency active pharmaceutical ingredients market are also focusing on launching new products to expand their product portfolio. In June 2020, Ajinomoto Biopharmaceutical Services Company launched AJILITY, a flexible and agile pharmaceutical platform designed to bring vaccines and therapies to the market while minimizing production time.
Key companies contributing in the global high potency active pharmaceutical ingredients market are Teva Pharmaceutical Industries Ltd., Roche Diagnostics, Pfizer Inc., Eli Lilly and Company, Bayer AG, SEQENS, BASF AG, Carbogen Amcis AG, Novartis International AG, Lonza, Sanofi Aventis, Minakem, Cambrex Corporation, SEQENS, Ajinomoto Bio-Pharma Services, MilliporeSigma, Merck & Co., Covidien Plc., Boehringer Ingelheim, and Bristol-Myers Squibb.
Reasons to Purchase this Report
Current and future of global High Potency Active Pharmaceutical Ingredients market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Buy This Complete A Business Report With Flat US $2000 Off @
Key companies in the global high potency active pharmaceutical ingredients market are focused on adopting M&A strategies to increase their market share. In June 2020, Ajinomoto BioPharma Services acquired Granules OmniChem Private Limited.
The major players in the market are also focusing on expanding production capacity to increase market share. In June 2018, Minafin’s CDMO division, Minakem, launched a new closed controlled environment and highly closed production facility for the production of highly effective active pharmaceutical ingredients.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire